Vaccine to prevent Shigella infections in young children
O-polysaccharide (OPS)-IpaB Conjugate Vaccine to Prevent Shigellosis
['FUNDING_R01'] · UNIVERSITY OF MARYLAND BALTIMORE · NIH-11090367
This study is testing a new vaccine designed to help protect young children under five from Shigella, a germ that causes bad diarrhea, to see if it can keep them healthy and safe from infections.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MARYLAND BALTIMORE (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-11090367 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new vaccine to protect young children from Shigella, a bacteria that causes severe diarrhea and can lead to long-term health issues. The vaccine aims to target two specific strains of Shigella and uses a unique protein to enhance immune response. By conducting trials, the researchers will assess the vaccine's safety and effectiveness in preventing infections, particularly in children under five years old who are most at risk. The approach is innovative as it combines different components to create a more effective immune response against this serious pathogen.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0 to 5 years, particularly those living in areas with limited access to clean water and sanitation.
Not a fit: Patients older than 5 years or those not at risk for Shigella infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of Shigella infections in young children, improving their health and quality of life.
How similar studies have performed: Previous research has shown promise in developing vaccines against Shigella, but this specific approach using the IpaB protein is novel and has not been extensively tested.
Where this research is happening
BALTIMORE, UNITED STATES
- UNIVERSITY OF MARYLAND BALTIMORE — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PASETTI, MARCELA F — UNIVERSITY OF MARYLAND BALTIMORE
- Study coordinator: PASETTI, MARCELA F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.